In-vitro activity of RP 59500, a new semisynthetic injectable pristinamycin against staphylococci.
We compared the in vitro activity of RP 59500, a new streptogramin, with that of vancomycin and ciprofloxacin against 130 strains of S. aureus and 117 strains of coagulase-negative staphylococci, using the agar dilution method. The antistaphylococcal activity of RP 59500 was similar to that of vancomycin. All staphylococcal strains were inhibited by < or = 2 micrograms/mL, including 61 methicillin-resistant S. aureus, 28 methicillin-resistant S. epidermidis and 23 methicillin-resistant S. haemolyticus strains. In contrast to ciprofloxacin, the in vitro activity of RP 59500 as well as of vancomycin remained almost unchanged, irrespective of the resistance phenotype for methicillin.
von Eiff
C
C
Institute of Medical Microbiology, Westfälische Wilhelms-Universität Münster, Germany.
Peters
G
G
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects*; D014769:Virginiamycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D014769:Virginiamycin; C062940:quinupristin-dalfopristin